September 2022 - Page 4 of 4 - BioMedWire (BMW)

TuesdaySep 06, 2022 11:22 am

Research Indicates Better Sleep Efficiency Benefits Fibromyalgia Sufferers

New research has found that improved sleep efficiency in patients who suffer from fibromyalgia and insomnia may improve their pain-related disorder. Fibromyalgia is a condition characterized by extensive musculoskeletal pain and tenderness, which is often accompanied by fatigue, mood and memory as well as sleep issues. The disorder is often caused by stressful events, which may include emotional, psychological or physical stress. Injuries or viral infections may also cause this pain disorder. On the other hand, insomnia is a sleep disorder that makes it hard for individuals to fall asleep or stay asleep. This common disorder may also cause individuals…

FridaySep 02, 2022 10:09 am

Study Highlights Need for Postnatal Depression Screening

Researchers at the University of Queensland have highlighted the need to screen for perinatal depression for women during the pregnancy period, after learning that women suffering from persistent depression have a heightened risk of developing the condition. Perinatal depression includes symptoms of depression, stress and anxiety that women sometimes experience from conception to a year following infant birth. The study’s objective was to assess the prevalence, timing of onset and duration of depression symptoms in the perinatal period in women with depression. The study involved more than 7,000 participants who were divided into two subgroups: women who had previously been…

ThursdaySep 01, 2022 10:58 am

Research Suggests Some 50% of Cancers Result from Preventable Factors

Cancer is said to be the second-leading cause of death globally, following heart disease. Among the different types of cancer, lung cancer is the leading cause of cancer death, followed by colorectal and liver cancers. A new study suggests that roughly 44% of the deaths caused by cancer can be attributed to risk factors that are preventable. These factors include drinking too much alcohol, smoking and having a high BMI. The researchers were focused on analyzing the relationship between cancer and various risk factors, using data obtained from the Global Burden of Disease project by the Institute for Health Metrics…

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to…